Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers

Core Insights - Aetna has joined UnitedHealthcare and Humana in providing Medicare Advantage coverage for the ReWalk Personal Exoskeleton, expanding access to approximately 16 million beneficiaries in the U.S. [1][2] Group 1: Company Developments - Lifeward Ltd. announced that Aetna issued prior authorization for a Medicare Advantage beneficiary to obtain the ReWalk Personal Exoskeleton, recognizing it as medically necessary for individuals with spinal cord injuries [1][2] - The ReWalk Personal Exoskeleton is an FDA-approved technology that enables individuals with spinal cord injuries to achieve functional ambulation, with multiple peer-reviewed studies supporting its benefits [2][3] Group 2: Market Impact - The recent approvals for prior authorization from three major Medicare Advantage insurers signify a significant advancement in access to exoskeletal rehabilitation technology for patients and providers [3][4] - A nurse with a spinal cord injury expressed that access to the ReWalk device represents a life-changing opportunity, emphasizing the importance of innovative mobility devices for dignity and independence [4] Group 3: Company Mission and Products - Lifeward is committed to driving innovation in medical technology to improve the lives of individuals with physical limitations or disabilities, with a product portfolio that includes the ReWalk Exoskeleton and other rehabilitation solutions [6][7]